Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study
Hoth Therapeutics (NASDAQ: HOTH) has reported promising early data from a preclinical study of its cancer treatment HT-KIT, conducted at NC State University. The preliminary results show that the treatment effectively stabilized tumor growth with remarkable consistency across subjects. Key findings include stabilized tumor volumes in treated subjects, high consistency across treated animals with minimal error bars, and notable differences compared to untreated controls which showed greater variability and increased tumor volume.
Hoth Therapeutics (NASDAQ: HOTH) ha riportato dati preliminari promettenti da uno studio preclinico sul suo trattamento per il cancro HT-KIT, condotto presso l'Università NC State. I risultati preliminari mostrano che il trattamento ha stabilizzato la crescita dei tumori con una notevole coerenza tra i soggetti. Risultati chiave includono volumi tumorali stabilizzati nei soggetti trattati, alta coerenza tra gli animali trattati con barre di errore minime e differenze significative rispetto ai controlli non trattati, che mostrano una maggiore variabilità e un aumento del volume tumorale.
Hoth Therapeutics (NASDAQ: HOTH) ha reportado datos preliminares prometedores de un estudio preclínico de su tratamiento contra el cáncer HT-KIT, realizado en la Universidad Estatal de Carolina del Norte. Los resultados iniciales muestran que el tratamiento estabilizó de manera efectiva el crecimiento del tumor con una notable consistencia entre los sujetos. Hallazgos clave incluyen volúmenes tumorales estables en los sujetos tratados, alta consistencia entre los animales tratados con márgenes de error mínimos, y diferencias notables en comparación con los controles no tratados, que mostraron mayor variabilidad y un aumento en el volumen del tumor.
Hoth Therapeutics (NASDAQ: HOTH)는 NC 주립대학교에서 실시한 암 치료 HT-KIT의 전임상 연구에서 유망한 초기 데이터를 보고하였습니다. 초기 결과는 치료가 종양의 성장을 효과적으로 안정화시켰으며, 여러 주제에서 놀라운 일관성을 보였음을 보여줍니다. 주요 발견으로는 치료받은 주제에서 안정된 종양 부피, 최소한의 오차 바를 가진 치료된 동물 간의 높은 일관성, 그리고 더 큰 변동성과 종양 부피 증가를 보인 비처리 대조군과의 주목할 만한 차이가 포함됩니다.
Hoth Therapeutics (NASDAQ: HOTH) a rapporté des données préliminaires prometteuses d'une étude préclinique sur son traitement du cancer HT-KIT, réalisée à l'Université NC State. Les résultats préliminaires montrent que le traitement stabilize efficacement la croissance tumorale avec une cohérence remarquable entre les sujets. Résultats clés incluent des volumes tumoraux stabilisés chez les sujets traités, une haute cohérence entre les animaux traités avec des barres d'erreur minimales et des différences notables par rapport aux témoins non traités, qui ont montré une plus grande variabilité et une augmentation du volume tumoral.
Hoth Therapeutics (NASDAQ: HOTH) hat vielversprechende frühzeitige Daten aus einer präklinischen Studie zu seiner Krebstherapie HT-KIT veröffentlicht, die an der NC State University durchgeführt wurde. Die vorläufigen Ergebnisse zeigen, dass die Behandlung das Tumorwachstum effektiv stabilisieren konnte, mit bemerkenswerter Konsistenz über alle Probanden hinweg. Wichtige Ergebnisse umfassen stabilisierte Tumorvolumina bei behandelten Probanden, hohe Konsistenz zwischen behandelten Tieren mit minimalen Fehlerbalken und bemerkenswerte Unterschiede zu unbehandelten Kontrollen, die eine größere Variabilität und ein erhöhtes Tumorvolumen aufwiesen.
- Treatment demonstrated effective tumor growth inhibition in preclinical studies
- High consistency in treatment response across all subjects
- Clear differentiation from untreated control group showing treatment efficacy
- Results are only preliminary and from preclinical phase
- Additional tissue data analysis still pending for full validation
Insights
The preclinical data for HT-KIT demonstrates promising tumor growth inhibition with remarkable consistency, a important factor in drug development. The uniformity in tumor volume response across treated subjects, indicated by minimal standard deviation, suggests robust reproducibility - a key indicator of treatment reliability. However, several critical aspects require attention:
- The study lacks specific quantitative data on tumor volume reductions
- Duration of treatment and sample size are not disclosed
- No safety or toxicity data is presented
- Mechanism of action details are absent
While these early results are encouraging for HOTH's oncology pipeline, investors should note that preclinical success doesn't guarantee clinical trial outcomes. The
The study measured tumor volumes in treated and untreated subjects over the course of the experiment. Tumor volume measurements in the treated group exhibited minimal changes, suggesting that the treatment effectively inhibited tumor growth. Additionally, all tumors in the treated animals displayed remarkable consistency in volume, with standard deviation error bars barely visible—a strong indication of the treatment's uniformity and reproducibility in suppressing tumor growth.
"These early findings are incredibly encouraging and demonstrate that our treatment has the potential to halt tumor progression consistently across subjects," said Robb Knie, CEO of Hoth Therapeutics. "The stability and low variability observed in tumor volumes among treated animals are indicative of a promising therapeutic effect, and we're excited to move forward with further testing as we process additional tissue data."
Key observations from the initial data include:
- Stabilized Tumor Growth: Tumor volumes in treated subjects remained remarkably stable over the course of the study, suggesting that the treatment may significantly inhibit tumor growth.
- Consistency Across Subjects: Tumor sizes were highly consistent across all treated animals, as demonstrated by the minimal error bars on the graph. This uniform response highlights the treatment's potential reproducibility and reliability.
- Comparison with Untreated Controls: In contrast, untreated subjects showed greater variability and an increase in tumor volume, underscoring the potential efficacy of the treatment in slowing or halting tumor growth.
As Hoth Therapeutics advances this research, the company will continue analyzing additional tissue data to further validate these results. The company is committed to moving forward with the development of this promising treatment and exploring its full potential for patients in need of effective cancer therapies.
For more information on Hoth Therapeutics' development programs, please visit www.hoththerapeutics.com.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/.
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email:
investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-update-on-cancer-therapeutic-ht-kit-results-suggesting-the-treatment-effectively-inhibited-tumor-growth-in-preclinical-treatment-study-302290406.html
SOURCE Hoth Therapeutics, Inc.
FAQ
What are the key findings from Hoth Therapeutics' (HOTH) HT-KIT cancer treatment study?
Where was the HT-KIT preclinical study conducted for Hoth Therapeutics (HOTH)?
What distinguishes the treated vs untreated results in HOTH's cancer treatment study?
